Advanced Filters
noise

Liver Disease Clinical Trials

A listing of Liver Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,453 clinical trials
J Julie Julie Bondgaard Løhde, MD

Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals

The investigators will conduct a proof-of-principle 4-weeks low-calorie diet (LCD) intervention study in low birth weight (LBW) subjects and normal birth weight (NBW) controls with documented (MR scan) liver fat content equal to or above 5%. The investigators will provide extended in-depth mechanistic insight into the role of impaired subcutaneous …

35 - 40 years of age All Phase N/A
V Vibeke Brix Christensen, MD, PhD, DMSc

BILACO Trial: Biliary Atresia - a Severe Complex Congenital Liver Disease

Biliary atresia is the most severe form of cholestatic liver disease. The children have high morbidity and mortality and get devastating pruritus and fatigue, failure to thrive, progressive hepatic failure and impaired neurodevelopment. The etiology is mostly unknown. More than half need a new liver from a living or deceased …

- 18 years of age All Phase N/A
P Pierre Emmanuel Rautou, Pr

Role of Coagulation, Inflammation and Vessels in Chronic Liver Disease

Chronic liver diseases represent a major public health problem and are responsible for more than 150,000 deaths in Europe each year. These diseases are accompanied by symptoms that profoundly alter the quality of life and mainly affect people of working age, leading to a major economic impact. Coagulation disorders, inflammation …

18 years of age All Phase N/A
T Teng-Yu Lee, MD, PhD

Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide and a significant public health issue. MASLD may progress to liver cirrhosis and/or hepatocellular carcinoma. Although previous evidence suggests that aspirin has antisteatotic and antifibrotic effects on the liver, a randomized controlled trial assessing long-term …

18 years of age All Phase 2
J Jimmy Che-To Lai

Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease

The goal of this randomised controlled trial is to evaluate the effect of carvedilol (a non-selective beta-blocker) in patients with compensated advanced chronic liver disease under clinically significant portal hypertension or the grey zone of Baveno VII criteria. The main question it aims to answer is: Does carvedilol reduce hepatic …

18 years of age All Phase 4
L Luisa Ronzoni

DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASE

Cholestatic disease in adults comprises a heterogeneous group of conditions characterized by intra- or extrahepatic alterations of bile flow that can lead to fibrosis or hepatic decompensation. Due to the heterogeneity of clinical manifestation, which is sometimes very subtle, diagnosis based on clinical, histological, and radiological evaluation is often very …

18 - 65 years of age All Phase N/A
M Michael Praktiknjo, MD

Vascular Liver Disease Evaluation, Follow Up and Non-Invasive Diagnostics Program

Background Vascular liver disorders (VALDI) are rare diseases, for which knowledge on risk factors, appropriate methods of diagnosis, effect of therapy and prognosis still need to be improved. Aim of the study This project aims to study risk factors, methods of detection, therapy and prognosis in order to elaborate and …

18 - 100 years of age All Phase N/A

Prospective Cohort, With Biobanking, of Patients With Nonalcoholic Fatty Liver Disease

The aim of the present prospective NAFLD cohort study (with biobank), of obese subjects with proven NAFLD based on liver biopsy and/or MRI, is to study factors contributing to the development of NASH in patients with simple steatosis and to identify and validate non-invasive markers for the diagnosis of NASH.

18 - 65 years of age All Phase N/A
S Soo Lim, MD, PHD

Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes

This exploratory study will assess the efficacy of combined pioglitazone and empagliflozin therapy in improving hepatic and metabolic outcomes in patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease (MAFLD). Although each agent has shown beneficial effects individually, evidence on their combined impact on liver health is …

20 years of age All Phase 4
A Andreas Cerny

Prospective Cohort and Biobank of Patients With Nonalcoholic Fatty Liver Disease

The goal of this observational study is to establish a unified cohort for retrospective and prospective high quality baseline and follow-up data registration of patients with a diagnosis of NAFLD/NASH/MAFLD, according to standardized criteria. This will allow future studies aimed at elucidate clinical presentation, natural history, response to treatment, genetic …

18 years of age All Phase N/A

Simplify language using AI